Bristol’s new myeloma CAR-T needs a hefty discount to be cost-effective, watchdogs say while endorsing GSK’s Blenrep

  • by
Bristol’s new myeloma CAR-T needs a hefty discount to be cost-effective, watchdogs say while endorsing GSK’s Blenrep
esagonowsky
Wed, 04/07/2021 – 09:45